| Day 1, Thursday, May 23rd | |
|---|---|
| 08:30-10:00 | BCMA-targeted therapies in myeloma: the new treatment frontier Pre-COMy CME Symposium |
| 10:00-10:20 | Coffee Break |
| 10:20-10:30 | COMy 2023 kick-off: Welcome by the Congress Co-Chairs |
| 10:30-12:00 | Session 1: Defining risk in myeloma |
| Moderators: Joan Bladé, Spain; TBA | |
| 10:30-10:45 | MGUS risk stratification: Shaji Kumar, USA |
| 10:45-11:00 | Smoldering myeloma risk stratification: Irene Ghobrial, USA |
| 11:00-11:15 | Ultra high-risk disease in IMS consensus: Jill Corre, France |
| 11:15-11:30 | Genomic landscape of high-risk disease: Eileen Boyle, USA |
| 11:30-11:45 | Frailty as a risk stratifier: Ceri Bygrave, UK |
| 11:45-12:00 | Discussion: should we design risk-based protocols? All session faculty and Hervé Avet-Loiseau, France & Vincent Rajkumar, USA |
| 12:00-12:30 | Lunch Break |
| 12:30-14:00 | Industry-supported Lunch Symposium |
| 14:00-14:10 | Technical Break |
| 14:10-15:35 | Session 2: Novel approaches for disease and response assessment |
| Moderators: Roberto Mina, Italy; Kwee Yong, UK | |
| 14:10-14:25 | Optimizing MRD assessment: Bruno Paiva, Spain |
| 14:25-14:40 | Mass spectrometry: Noemi Puig, Spain |
| 14:40-14:55 | Immune monitoring in the context of immunotherapy: Niels van de Donk, Netherlands |
| 14:55-15:10 | Advances in imaging techniques: Elena Zamagni, Italy |
| 15:10-15:25 | The microbiota signature: Florent Malard, France |
| 15:25-15:35 | Discussion: should we design risk-based protocols? All session faculty and Gordon Cook, UK & Jesús San Miguel, Spain |
| 15:35-15:45 | Technical Break |
| 15:45-17:15 | Industry-supported Symposium |
| 17:15-17:30 | Coffee Break |
| 17:30-18:30 | Session 3: Precursor conditions and other plasma cell disorders |
| Moderators: Michel Delforge, Belgium; Murielle Roussel, France | |
| 17:30-17:45 | Screening for MGUS: hype or reality? Sigurdur Kristinsson, Iceland |
| 17:45-18:00 | Diagnosis and management of amyloidosis: Giampaolo Merlini, Italy |
| 18:00-18:15 | Diagnosis and management of Waldenström macroglobulinemia: Steven Treon, USA |
| 18:15-18:30 | Discussion: should we treat precursor conditions? All session faculty and Bertrand Arnulf, France & Fredrik Schjesvold, Norway |
| 18:30-19:15 | Session 4: Plenary lectures |
| Moderators: Holger Auner, Switzerland; Charlotte Pawlyn, UK | |
| 18:30-18:50 | Genomics of myeloma: the latest advances: Nikhil Munshi, USA |
| 18:50-19:15 | New mechanisms of disease resistance to T cell-based therapies: Paola Neri, Canada |
| Day 2, Friday, May 24th | |
|---|---|
| 08:15-08:25 | Good Morning Breakfast |
| 08:25-09:25 | Session 5: IMS Session |
| Moderators: Philippe Moreau, France; Nikhil Munshi, USA | |
| 09:25-09:35 | Technical Break |
| 09:35-11:05 | Industry-supported Morning Symposium |
| 11:05-11:20 | Coffee Break |
| 11:20-12:30 | Session 6: Frontline management of newly diagnosed myeloma |
| Moderators: Mario Boccadoro, Italy; TBA | |
| 11:20-11:35 | The optimal induction prior to transplant: Francesca Gay, Italy |
| 11:35-11:50 | The role of double transplant: Hartmut Goldschmidt, Germany |
| 11:50-12:05 | The evolving landscape of maintenance therapy: Laura Rosiñol, Spain |
| 12:05-12:20 | The optimal approach in very old and frail patients: Thierry Facon, France |
| 12:20-12:30 | Discussion: should we continue to transplant myeloma? All session faculty and Michele Cavo, Italy & Katja Weisel, Germany |
| 12:30-13:00 | Lunch Break |
| 13:00-14:30 | Industry-supported Lunch Symposium |
| 14:30-14:45 | Technical Break |
| 14:45-15:45 | Session 7: Practical management of specific situations |
| Moderators: Meral Beksac, Turkey; Lalit Kumar, India | |
| 14:45-15:00 | Extra-medullary disease: Philippe Moreau, France |
| 15:00-15:15 | Therapy of patients under dialysis: Aurore Perrot, France |
| 15:15-15:30 | Bone disease: the latest guidelines: Evangelos Terpos, Greece |
| 15:30-15:45 | Vaccinations and infectious prophylaxis: Heinz Ludwig, Germany |
| 15:45-16:00 | Coffee Break |
| 16:00-17:30 | Industry-supported Symposium |
| 17:30-17:45 | Technical Break |
| 17:45-18:45 | Session 8: Plenary lectures |
| Moderators: Suzanne Lentzsch, USA; Saad Usmani, USA | |
| 17:45-18:00 | CAR-T cells: present and future: Hermann Einsele, Germany |
| 18:00-18:15 | Bispecific antibodies: present and future: Nizar Bahlis, Canada |
| 18:15-18:30 | Minimizing toxicities after immunotherapy: Salomon Manier, France |
| 18:30-18:45 | Discussion: how to sequence immunotherapies? All session faculty and Ajai Chari, USA & Thomas Martin, USA |
| 18:45-19:45 | Award Ceremony Session: Presented by the Congress Co-Chairs |
| Day 3, Saturday, May 25th | |
|---|---|
| 08:00-08:10 | Good Morning Breakfast |
| 08:10-09:10 | Session 9: Novel agents under development |
| Moderators: Michael O’Dwyer, Ireland; Rakesh Popat, UK | |
| 08:10-08:25 | CELMODs: Sagar Lonial, USA |
| 08:25-08:40 | Antibody-drug conjugates: Fredrik Schjesvold, Norway |
| 08:40-08:55 | Peptide conjugates: Enrique Ocio, Spain |
| 08:55-09:10 | How to bridge patients prior to CAR-T cells? Paul Richardson, USA |
| 09:10-09:20 | Technical Break |
| 09:20-10:50 | Is there a place for BCMA-based combinations in early RRMM? Industry-supported Morning Symposium |
| 10:50-11:10 | Coffee Break |
| 11:10-12:25 | Session 10: How I treat a relapsed/refractory myeloma |
| Moderators: Bhagirathbhai Dholaria, USA;Joseph Mikhael, USA | |
| 11:10-11:25 | Clinical case presentation + Treatment options (1st relapse after transplant): Cyrille Touzeau, France |
| 11:25-11:40 | Clinical case presentation + Treatment options (1st relapse after anti-CD38+Rd): Alessandra Larocca, Italy |
| 11:40-11:55 | Clinical case presentation + Treatment options (triple class refractory young patient): Xavier Leleu, France |
| 11:55-12:10 | Clinical case presentation + Treatment options (triple class refractory elderly patient): Hira Mian, Canada |
| 12:10-12:30 | Discussion All session faculty and Claudio Cerchione, Italy & Joshua Richter, USA |
| 12:30-13:00 | Lunch Break |
| 13:00-14:00 | An innovative therapeutic option in the treatment of triple-class exposed relapsed refractory multiple myeloma (TCE RRMM) Industry-supported Lunch Symposium |
| 14:00-14:10 | Technical Break |
| 14:10-14:55 | Management of triple-class refractory patients in the absence of immunotherapies |
| Chairs: Mohamad Mohty, France; Lisa Leypoldt, Germany | |
| 14:10-14:25 | Case study presentation: Bhagirathbhai Dholaria, USA |
| 14:25-14:40 | XPO-1 inhibition for refractory myeloma: Lisa Leypoldt, Germany |
| 14:40-14:55 | Discussion All session faculty |
| 14:55-16:10 | Session 11: The road to cure: future protocols and directions |
| Moderators: Vincent Rajkumar, USA; TBA | |
| 14:55-15:10 | Young and fit patients: Pieter Sonneveld, Netherlands |
| 15:10-15:25 | Elderly and/or frail patients: Sonja Zweegman, Netherlands |
| 15:25-15:40 | Protocols for low- and middle-income countries: Vania Hungria, Brazil |
| 15:40-15:55 | How to design the best protocol? Jean-Luc Harousseau, France |
| 15:55-16:10 | Patients’ perspective and advocacy: Brian Durie, USA |
| 16:10-16:30 | Coffee Break |
| 16:30-17:30 | CME Symposium |
| 17:30-17:40 | Technical Break |
| 17:40-18:10 | Session 12: Plenary lecture |
| Moderators: Congress Co-Chairs | |
| 17:40-18:10 | Curing myeloma: from the bench to the bedside: Kenneth Anderson, USA |
| 18:10-18:20 | In-Person Conclusions: Summary by the Congress Co-Chairs |
| Day 4 (ONLINE ONLY), Sunday, May 26th |
|
|---|---|
| 10:15-11:30 | Multiple Myeloma communications I |
| Moderators: TBA | |
| 10:15-10:30 | EFFICACY OF MELFLUFEN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND MUTATED OR DELETED TP53 Klara Acs, Sweden |
| 10:30-10:45 | OUTCOMES OF PATIENTS WITH EXTRAMEDULLARY DISEASE IN TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMMOTION + MOMMENT STUDIES Philippe Moreau, France |
| 10:45-11:00 | EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE-RISK OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): FINAL ANALYSIS OF THE PHASE 2 CENTAURUS STUDY Hartmut Goldschmidt, Germany |
| 11:00-11:15 | PHASE 2 CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL IN MULTIPLE MYELOMA AND 1–3 PRIOR LINES (COHORT A) AND WITH EARLY RELAPSE AFTER FRONTLINE TREATMENT (COHORT B) Michel Delforge, Belgium |
| 11:15-11:30 | Discussion |
| 11:30-12:30 | Transforming Progress into Action in Relapsed/Refractory Multiple Myeloma CME Virtual Symposium |
| 12:30-13:45 | Multiple Myeloma communications II |
| Moderators: TBA | |
| 12:30-12:45 | UPDATED RESULTS OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH PRIOR EXPOSURE TO T-CELL REDIRECTING THERAPIES: RESULTS OF THE PHASE 1/2 MONUMENTAL-1 STUDY Philippe Moreau, France |
| 12:45-13:00 | SELINEXOR, IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN FUNCTIONALLY HIGH-RISK MULTIPLE MYELOMA: RESULTS FROM THE MYELOMA DEVELOPING REGIMENS USING GENOMICS (MYDRUG) SUB-PROTOCOL Y3 Joshua Richter, USA |
| 13:00-13:15 | THE RISING UNMET NEED FOR MULTIPLE MYELOMA PATIENTS AFTER FIRST-LINE TREATMENT WITH DRD: AN EPIDEMIOLOGICAL ESTIMATE IN ITALY BETWEEN 2024-2028 Francesca Fiorentino, Italy |
| 13:15-13:30 | LINVOSELTAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-TARGETED T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES DEEP AND DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) INCLUDING DIFFICULT-TO-TREAT SUBGROUPS Sundar Jagannath, USA |
| 13:30-13:45 | Discussion |
| 13:45-14:15 | Final Panel Discussion and Conclusion |